The true toxicity of Veklury © (remdesivir)
Did the Gilead company hide the true toxicity of Veklury © (remdesivir) ?
Concerns about the approval and widespread use of Veklury © (remdesivir) for treating COVID-19, questioning its efficacy, toxicity, and potential hidden side effects.
The analysis criticizes the lack of clear data on the drug's safety profile, highlighting the absence of information on adverse events and drug interactions.
We the peoples suggests that the pharmaceutical company, Gilead, may be downplaying the toxicity of Remdesivir and calls for a thorough investigation into its potential harm.
The article also questions the timing of Veklury's © introduction into the market, emphasizing the need for transparency and comprehensive safety assessments before endorsing its widespread use.
Did the Gilead company hide the true toxicity of Veklury © (remdesivir) ?
Written by @france_soir & @xazalbert Translated by Your’s truly,
Efficacy Concerns
The article questions the efficacy of Veklury © in treating COVID-19, emphasizing that the benefits seem modest, primarily focusing on a reduction in hospital stay without a significant impact on mortality.
The positioning of Veklury © at an advanced stage of the disease is criticized, as many argue that antivirals are typically more effective in the early stages of viral infections.
Toxicity Issues
Serious concerns are raised about the lack of comprehensive studies on the toxicity of the main components of Veklury ©, GS-5734, and its metabolite GS-441524.
The article highlights potential toxicity issues, pointing to reported serious side effects, including elevations of ALT, renal insufficiencies, and cases requiring renal transplantation.
Lack of transparency from Gilead regarding side effects and drug interactions is noted, raising questions about the true safety of the drug.
Controversial Approval Process
The article questions the decisions of international health authorities, such as the WHO, FDA, and EMA, to authorize the use of Veklury ©, especially when considering the limited demonstrated benefits and potential safety concerns.
There's a call for a re-analysis of the data and additional information regarding the approval process, highlighting discrepancies in the information provided by Gilead and health authorities.
Conclusion
The article concludes by expressing the need for official scrutiny of Veklury ©, requesting transparency and more comprehensive data to ensure the safety and efficacy of the drug.
The possibility of a hidden agenda, with the media focus on discrediting other treatments like hydroxychloroquine, is suggested, emphasizing the urgency of addressing the concerns surrounding Veklury ©.
Annexes
The article includes additional sections (Annex I and Annex II) providing detailed insights into the lack of available information on toxicity, potential issues with genotoxicity data, and the manufacturing precautions of remdesivir, including its classification as a hyper-toxic and corrosive nitrile.
This summary covers the key points of your provided content, and an article structured around these main points would likely delve into each aspect in more detail, presenting evidence and arguments to support the concerns raised.
Did the Gilead company hide the true toxicity of Veklury © (remdesivir) ?
The Buried Truth Won’t Stay Buried for Long
https://www.globalresearch.ca/remdesivir-covid-19-1-6-billion-modestly-beneficial-drug/5717690/amp
More here: